MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?

Amir Abbas Momtazi, Maciej Banach, Matteo Pirro, Evan A. Stein, Amirhossein Sahebkar

Research output: Contribution to journalReview articlepeer-review

23 Citations (Scopus)


Familial hypercholesterolemia (FH) is the most common inherited form of dyslipidemia and a major cause of premature cardiovascular disease. Management of FH mainly relies on the efficiency of treatments that reduce plasma low-density lipoprotein (LDL) cholesterol (LDL-C) concentrations. MicroRNAs (miRs) have been suggested as emerging regulators of plasma LDL-C concentrations. Notably, there is evidence showing that miRs can regulate the post-transcriptional expression of genes involved in the pathogenesis of FH, including LDLR, APOB, PCSK9, and LDLRAP1. In addition, many miRs are located in genomic loci associated with abnormal levels of circulating lipids and lipoproteins in human plasma. The strong regulatory effects of miRs on the expression of FH-associated genes support of the notion that manipulation of miRs might serve as a potential novel therapeutic approach. The present review describes miRs-targeting FH-associated genes that could be used as potential therapeutic targets in patients with FH or other severe dyslipidemias.

Original languageEnglish
Pages (from-to)224-233
Number of pages10
JournalClinical Reviews in Allergy and Immunology
Issue number2
Publication statusPublished - 1 Apr 2018


Dive into the research topics of 'MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?'. Together they form a unique fingerprint.

Cite this